Renal fibrosis: Recent translational aspects.

Area of Science:

• Nephrology
• Pathology
• Pharmacology

Background:

• Renal fibrogenesis, characterized by extracellular matrix deposition, is a common outcome of kidney injury leading to Chronic Kidney Disease (CKD).
• Current treatments targeting the renin-angiotensin system, like ACE inhibitors and ARBs, were established 20 years ago and lack novel alternatives.
• There is a critical need for new therapeutic strategies and reliable biomarkers to effectively manage renal fibrogenesis and CKD progression.

Purpose of the Study:

• To review recent advancements in understanding renal fibrogenesis pathways.
• To identify novel therapeutic targets with high potential for treating renal fibrosis in humans.
• To highlight promising biomarkers for quantifying renal fibrosis.

Main Methods:

• Literature review of recent scientific publications.
• Analysis of emerging pathways implicated in renal fibrogenesis.
• Evaluation of potential therapeutic targets and biomarkers for clinical relevance.

Main Results:

• Identification of several novel molecular pathways driving renal fibrogenesis.
• Assessment of the therapeutic potential of targeting these pathways.
• Discussion of promising biomarkers for monitoring fibrosis progression and treatment response.

Conclusions:

• Novel therapeutic targets and biomarkers are crucial for advancing the treatment of renal fibrogenesis and CKD.
• Further research into these emerging pathways could lead to more effective interventions.
• Accurate biomarkers are needed to precisely quantify renal fibrosis and guide clinical decisions.